Oppenheimer raised the firm’s price target on Zimmer Biomet to $155 from $150 and keeps an Outperform rating on the shares. Zimmer’s Q1 EPS and sales were ahead of the firm’s estimates, with U.S. knees serving as the primary outperformer, and the Q2 guidance looks conservative, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet backs FY24 adjusted EPS view $8.00-$8.15, consensus $8.06
- Zimmer Biomet reports Q1 adjusted EPS $1.94, consensus $1.87
- Zimmer Biomet Announces First Quarter 2024 Financial Results
- Notable companies reporting before tomorrow’s open
- Zimmer Biomet becomes official medical device partner of U.S. pickleball